Efficacy and safety of conversion from cyclosporine to everolimus in living‐donor kidney transplant recipients: an analysis from the ZEUS study

Summary Conversion of living‐donor kidney transplant patients from calcineurin inhibitor therapy to an mTOR inhibitor is poorly documented. In the prospective, multicentre ZEUS study, 300 kidney transplant recipients without prior rejection (Banff grade >1) and serum creatinine ≤265 μmol/l were r...

Full description

Saved in:
Bibliographic Details
Published in:Transplant international 2014-11, Vol.27 (11), p.1192-1204
Main Authors: Lehner, Frank, Budde, Klemens, Zeier, Martin, Wüthrich, Rudolf P., Reinke, Petra, Eisenberger, Ute, Mühlfeld, Anja, Arns, Wolfgang, Stahl, Rolf, Heller, Katharina, Witzke, Oliver, Wolters, Heiner H., Suwelack, Barbara, Klehr, Hans Ulrich, Stangl, Manfred, Hauser, Ingeborg A., Nadalin, Silvio, Porstner, Martina, May, Christoph, Paulus, Eva‐Maria, Sommerer, Claudia
Format: Article
Language:English
Subjects:
Adult
calcineurin inhibitors
Calcineurin Inhibitors - administration & dosage
Calcineurin Inhibitors - adverse effects
Cohort Studies
cyclosporine
Cyclosporine - administration & dosage
Cyclosporine - adverse effects
Drug Administration Schedule
Drug therapy
Everolimus
Female
Glomerular Filtration Rate
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Kidney Transplantation
living donor
Living Donors
Male
Middle Aged
Prospective Studies
renal function
Sirolimus - administration & dosage
Sirolimus - adverse effects
Sirolimus - analogs & derivatives
TOR Serine-Threonine Kinases - antagonists & inhibitors
Transplant Recipients
Transplants & implants
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Conversion of living‐donor kidney transplant patients from calcineurin inhibitor therapy to an mTOR inhibitor is poorly documented. In the prospective, multicentre ZEUS study, 300 kidney transplant recipients without prior rejection (Banff grade >1) and serum creatinine ≤265 μmol/l were randomized to continue cyclosporine or convert to everolimus at 4.5 months post‐transplant. In a post hoc analysis of 80 living‐donor recipients, adjusted estimated GFR (Nankivell) at month 12 (the primary endpoint) was 74.3 (95% CI [70.7, 77.9]) ml/min/1.73 m2 with everolimus versus 63.8 (95% CI [60.0, 67.7]) ml/min/1.73 m2) with cyclosporine, a difference of 10.5 ml/min/1.73 m2 in favour of everolimus (P 
ISSN:0934-0874
1432-2277
DOI:10.1111/tri.12411